about
Killing cancer cells by targeted drug-carrying phage nanomedicinesTherapeutic antibodies, vaccines and antibodyomesPreclinical development of monoclonal antibodies: considerations for the use of non-human primatesPositive and negative functions of B lymphocytes in tumorsLinkers Having a Crucial Role in Antibody-Drug ConjugatesMerkel cell carcinoma of the head and neck: pathogenesis, current and emerging treatment optionsAntibody-drug conjugates as novel anti-cancer chemotherapeuticsMultiple cues on the physiochemical, mesenchymal, and intracellular trafficking interactions with nanocarriers to maximize tumor target efficiencyTissue distribution studies of protein therapeutics using molecular probes: molecular imagingApplications of calixarenes in cancer chemotherapy: facts and perspectivesInterferons as inducers of apoptosis in malignant cellsTargeted therapy using nanotechnology: focus on cancerTargeted chelation therapy with EDTA-loaded albumin nanoparticles regresses arterial calcification without causing systemic side effects.Synthetic antibodies for specific recognition and crystallization of structured RNAPractical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodiesAntibody drug-conjugates targeting the tumor vasculature: Current and future developments"Eat me" imaging and therapyGamma-secretase inhibitor treatment promotes VEGF-A-driven blood vessel growth and vascular leakage but disrupts neovascular perfusionQuantitative assessment of antibody internalization with novel monoclonal antibodies against Alexa fluorophoresTherapeutic antibodies: current state and future trends--is a paradigm change coming soon?Biology by design: reduction and synthesis of cellular components and behaviourAnticalins: the lipocalin family as a novel protein scaffold for the development of next-generation immunotherapies.Listeriolysin O as cytotoxic component of an immunotoxinSelective intracellular vaporisation of antibody-conjugated phase-change nano-droplets in vitroExceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies.Novel multifunctional pH-sensitive nanoparticles loaded into microbubbles as drug delivery vehicles for enhanced tumor targetingTop-down mass spectrometry for the analysis of combinatorial post-translational modifications.Ultrasonic-activated micellar drug delivery for cancer treatment.Inhibition of tumor metastasis: functional immune modulation of the CUB domain containing protein 1.Bispecific engineered antibody domains (nanoantibodies) that interact noncompetitively with an HIV-1 neutralizing epitope and FcRn.Identification of accessible human cancer biomarkers using ex vivo chemical proteomic strategies.Human anti-gold antibodies: biofunctionalization of gold nanoparticles and surfaces with anti-gold antibodies.A yeast display immunoprecipitation method for efficient isolation and characterization of antigens.Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets.Efficient production of human bivalent and trivalent anti-MUC1 Fab-scFv antibodies in Pichia pastorisRecent trends in targeted anticancer prodrug and conjugate design.Antibody library screens using detergent-solubilized mammalian cell lysates as antigen sources.Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12.Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapiesTargeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma.
P2860
Q21256651-D0412A42-A36A-451A-99B8-4816CAD57717Q24599662-2721B874-7985-48EB-9D2F-3BC80211E41CQ24655266-AE56C82E-018B-4D85-BECB-BB8473F25E87Q26743398-E4141DC2-BC6F-4DA9-B2EF-3599D11117D4Q26752763-2AD6A107-8184-485F-9B31-AEF418D06070Q26796421-67D19C6E-006D-47EA-AD7A-351B3ECA1AE7Q26800175-4BC780E2-C0BB-44A4-8828-E11DC8F9386BQ26827999-134E4F6A-A9B0-4A90-8DA6-8BE5C1D5D451Q26865516-DDF3D213-E1AB-4718-BD8B-F5496459C902Q26995815-D32D4F19-E361-4DA0-A60A-ED0058AE891DQ27010207-95EC9A59-4DE4-498E-9AA0-F3809D6B1403Q27023361-1BDE07DF-7555-4E39-93F9-88F2E0E68795Q27310025-7BEEBFC3-5FF2-4E1D-AC43-4550A9FDA70EQ27649448-19E175BA-80EA-495F-8972-B400A4FF26D3Q27690917-4D04557D-EB87-4EE0-9984-8845DDDFCF7FQ28270261-892294E8-6F29-49FA-A0B5-2561634C5CE3Q28394148-83D1ED78-9316-4201-9EC3-1A660D238104Q28477769-A6939825-DD1E-48EF-86E3-73EC7EFB58FBQ28546526-01033C00-A7AB-431E-8CB9-91E3CFA48CCEQ28728956-CCBCB3EC-4245-4D4C-A225-D752C2B4281AQ28754680-2FA15836-7222-4BC1-92F3-86C6CB9EBB3FQ30157932-BEE6F5C3-61B4-4CA1-930D-D1C450A12738Q30319103-22781DEB-54E1-455C-8BA1-9A72441062E3Q30360403-400BD5D2-90A0-4E86-A5AE-241235B8FE26Q30362113-BD92DF1C-EBF3-49B5-AE27-FAC2880742A9Q30379739-844CC6CB-9C3E-4118-974D-84A0DD148025Q30418309-4208DA0C-DDA6-4A6B-B4AD-65AB9A05D9DBQ30490995-FA59C225-B0FF-4087-9B8F-E224D5833CF3Q30886371-95AE341D-D876-4248-9352-3F339FC50B07Q31082210-5D4B0445-07DE-4036-BD12-79D44E6F7DE7Q33309341-BF027AA3-EFC7-462B-9735-55A5E60F2B0CQ33379776-26DA9D81-2F09-4DD0-AB8D-1002078EC1C7Q33388079-56D781BC-485A-43A7-8814-0DDB348C5D44Q33402525-0C3B950C-F205-4838-9914-B8103CE7CBBAQ33492560-4C789DEC-81E6-43F0-9D59-5411A4A882EDQ33573762-35E7FAB0-3E52-4614-ACE4-4ED8FB038B34Q33585960-DA85C496-59E6-4ACA-A976-CD716A8A9F84Q33605532-8920AB9D-7C5F-48B8-B96B-9410B977AFFAQ33730375-ECCCDBB7-6720-4D04-A004-FC1F0C69E257Q33788697-AF648EA0-2015-4C46-A59A-DF56E8A94BCE
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Antibody targeted drugs as cancer therapeutics.
@ast
Antibody targeted drugs as cancer therapeutics.
@en
type
label
Antibody targeted drugs as cancer therapeutics.
@ast
Antibody targeted drugs as cancer therapeutics.
@en
prefLabel
Antibody targeted drugs as cancer therapeutics.
@ast
Antibody targeted drugs as cancer therapeutics.
@en
P2093
P2860
P356
P1476
Antibody targeted drugs as cancer therapeutics.
@en
P2093
David Schrama
Jürgen C Becker
Ralph A Reisfeld
P2860
P2888
P304
P356
10.1038/NRD1957
P577
2006-02-01T00:00:00Z